Novartis' Afinitor performs in pancreatic cancer trial

Novartis' (NYSE:NVS) cancer drug Afinitor helps patients with pancreatic cancer live longer without tumor growth, a late-stage trial showed, giving the company a boost ahead of the biggest annual cancer meeting. Release | Report